Blog Chatter Suggests "People Following The Situation Have Heard Speculation Arrowhead Pharmaceuticals Recently Rebuffed An Indicative Approach Pitched At Around $45 A Share."; Shares Spiking Higher
Author: Benzinga Newsdesk | February 28, 2024 02:20pm